CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 27 enrolled
Drug / intervention
Topotecan +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00548418
NCT00548418Phase 2Completed
CompareCT.gov

Phase II Trial of Topotecan, Cisplatin and Bevacizumab for Recurrent/Persistent Cervical Cancer

Washington University School of Medicine·interventional·Posted Oct 24, 2007·Updated Aug 1, 2014

In Brief

A Phase 2 clinical trial evaluating Topotecan, Cisplatin, and 1 other intervention for Cervical Cancer. Completed, enrolled 27 participants across 3 sites.

Detailed Summary

The purpose of this study is to determine whether the combination of topotecan, cisplatin and bevacizumab is effective in the treatment of recurrent or persistent cervical cancer

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCervical Cancer
CountriesUnited States
CollaboratorsGlaxoSmithKline, Genentech, Inc.

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 24, 2007
Enrollment StartFeb 1, 2007
Primary CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 18.7 years ago

Interventions

Topotecandrug

Cisplatindrug

Bevacizumabdrug